Zoledronate trisodium hydrate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412656

CAS#: 165800-08-8 (trisodium hydrate)

Description: Zoledronate trisodium is a Bone Resorption Inhibitor and Osteoporosis Therapy Adjunct

Chemical Structure

img
Zoledronate trisodium hydrate
CAS# 165800-08-8 (trisodium hydrate)
Instruction

Theoretical Analysis

MedKoo Cat#: 412656
Name: Zoledronate trisodium hydrate
CAS#: 165800-08-8 (trisodium hydrate)
Chemical Formula: C25H39N10Na15O37P10
Exact Mass: 0.00
Molecular Weight: 1,726.200
Elemental Analysis: C, 17.40; H, 2.28; N, 8.11; Na, 19.98; O, 34.29; P, 17.94

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 118072-93-8 (free acid)   165800-06-6 (free acid hydrate)   131654-46-1 (disodium)   827573-11-5 (trisodium)   165800-07-7 (disodium hydrate)   165800-08-8 (trisodium hydrate)    

Synonym: Zoledronate trisodium, Zoledronate trisodium hydrate

IUPAC/Chemical Name: Phosphonic acid, (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bis-, trisodium compound with water (5:2)

InChi Key: HYMYRPXSMHJPGD-UHFFFAOYSA-A

InChi Code: InChI=1S/5C5H10N2O7P2.15Na.2H2O/c5*8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;;;;;;;;;;;;;;;;;/h5*1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);;;;;;;;;;;;;;;;2*1H2/q;;;;;15*+1;;/p-15

SMILES Code: OC(P([O-])([O-])=O)(P([O-])(O)=O)CN1C=CN=C1.OC(P([O-])([O-])=O)(P([O-])(O)=O)CN2C=CN=C2.OC(P([O-])([O-])=O)(P([O-])(O)=O)CN3C=CN=C3.OC(P([O-])([O-])=O)(P([O-])(O)=O)CN4C=CN=C4.OC(P([O-])([O-])=O)(P([O-])(O)=O)CN5C=CN=C5.[H]O[H].[H]O[H].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,726.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD. Fracture Prevention with Zoledronate in Older Women with Osteopenia. N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082. Epub 2018 Oct 1. PMID: 30575489.

2: Bergua A, Hohberger B. Zoledronsäure-induzierte Panuveitis [Zoledronate- induced panuveitis]. Ophthalmologe. 2018 Jul;115(7):592-594. German. doi: 10.1007/s00347-017-0538-3. PMID: 28748264.

3: Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial. J Bone Miner Res. 2019 Dec;34(12):2220-2228. doi: 10.1002/jbmr.3853. Epub 2019 Oct 14. PMID: 31433518.

4: Leong I. Zoledronate prevents fractures in osteopenia. Nat Rev Endocrinol. 2018 Dec;14(12):688. doi: 10.1038/s41574-018-0116-z. PMID: 30353074.

5: Dong W, Qi M, Wang Y, Feng X, Liu H. Zoledronate and high glucose levels influence osteoclast differentiation and bone absorption via the AMPK pathway. Biochem Biophys Res Commun. 2018 Nov 10;505(4):1195-1202. doi: 10.1016/j.bbrc.2018.10.059. Epub 2018 Oct 13. PMID: 30322621.

6: Zhao Z, Shen W, Zhu H, Lin L, Jiang G, Zhu Y, Song H, Wu L. Zoledronate inhibits fibroblasts' proliferation and activation via targeting TGF-β signaling pathway. Drug Des Devel Ther. 2018 Sep 17;12:3021-3031. doi: 10.2147/DDDT.S168897. PMID: 30271117; PMCID: PMC6147205.

7: He Y, Bao W, Wu XD, Huang W, Chen H, Li Z. Effects of Systemic or Local Administration of Zoledronate on Implant Osseointegration: A Preclinical Meta- Analysis. Biomed Res Int. 2019 Sep 22;2019:9541485. doi: 10.1155/2019/9541485. PMID: 31663000; PMCID: PMC6778941.

8: Zhao QH, Zhang XS, Wu K, Zhang J, Xia TF, Chen J, Qin ZS, Pang LQ. Preparation of Zoledronate liposome and its impact on apoptosis of Kupffer cells in rat liver. Acta Cir Bras. 2018 Dec;33(12):1052-1060. doi: 10.1590/s0102-865020180120000002. PMID: 30624510.

9: Schenk A, Lux C, Lane J, Martin O. Evaluation of Zoledronate as Treatment for Hypercalcemia in Four Dogs. J Am Anim Hosp Assoc. 2018 Nov/Dec;54(6):e54604. doi: 10.5326/JAAHA-MS-6681. Epub 2018 Oct 1. PMID: 30272485.

10: Zandi M, Shokri A, Mousavi M, Rajaei S, Mohammad Gholi Mezerji N. Does zoledronate therapy make mandibular bone susceptible to fracture? A radiographical and biomechanical study in rats. Injury. 2018 Oct;49(10):1746-1749. doi: 10.1016/j.injury.2018.07.006. Epub 2018 Jul 6. PMID: 30007517.